Evidence map›Paper›PMID 40016487›Full record

Trial reportNature cancer2025

Neoadjuvant cabozantinib for locally advanced nonmetastatic clear cell renal cell carcinoma: a phase 2 trial.

Mehmet A Bilen, BaoHan T Vo, Yuan Liu, Rachel Greenwald, Amir H Davarpanah, Donald McGuire, Rakesh Shiradkar, Liping Li, Adhishek Midya, Bassel Nazha and 23 more

Registry-linked trialAbstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Nature cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04022343 (A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma), which is not on this map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04022343 phase2active not recruitingnot on this map

A Phase 2 Study of Neoadjuvant Cabozantinib in Patients With Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma

TypeinterventionalSponsorEmory UniversityRan2019 to 2026Enrolled22ConditionsClear Cell Renal Cell Carcinoma, Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8ArmsCabozantinib
3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

33 authors.

Mehmet A Bilen *Winship Cancer Institute of Emory University, Atlanta, GA, USA. Mehmet.a.bilen@emory.edu.ORCID http://orcid.org/0000-0003-4003-1103
BaoHan T Vo *Department of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0009-0009-5179-1889
Yuan LiuWinship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-8926-3058
Rachel GreenwaldDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3139-5079
Amir H DavarpanahDepartment of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, GA, USA.
Donald McGuireDepartment of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-3742-9594
Rakesh ShiradkarWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Liping LiWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0009-0009-9064-2456
Adhishek MidyaWallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA, USA.
Bassel NazhaWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Jacqueline T BrownWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Sierra WilliamsDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Wilena SessionWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Greta RusslerWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Sarah CaulfieldWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Shreyas S JoshiWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Vikram M NarayanWinship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0003-3731-4209
Christopher P FilsonDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Kenneth OganWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Omer KucukWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Bradley Curtis CarthonWinship Cancer Institute of Emory University, Atlanta, GA, USA.
Luke Del BalzoDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Athena CohenDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Adriana BoyantonDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Nataliya ProkhnevskaDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Maria Andrea CardenasDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.ORCID http://orcid.org/0000-0002-8566-9576
Ewelina SobierajskaDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Caroline S JansenWinship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-9128-2004
Dattatraya H PatilDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Edouard NicaiseDepartment of Urology, Emory University School of Medicine, Atlanta, GA, USA.
Adeboye O OsunkoyaWinship Cancer Institute of Emory University, Atlanta, GA, USA.ORCID http://orcid.org/0000-0001-5712-8134
Haydn T KissickWinship Cancer Institute of Emory University, Atlanta, GA, USA. haydn.kissick@emory.edu.ORCID http://orcid.org/0000-0001-7624-5598
Viraj A MasterWinship Cancer Institute of Emory University, Atlanta, GA, USA. vmaster@emory.edu.ORCID http://orcid.org/0000-0002-7251-142X

Funding

Exelis 7325000250
6 · The paper itself

Abstract

Cabozantinib is an oral multikinase inhibitor approved for treatment in metastatic renal cell carcinoma (RCC). We conducted a phase 2, nonrandomized, single-arm clinical trial (NCT04022343) of cabozantinib treatment for 12 weeks in 17 patients with locally advanced, biopsy-proven, nonmetastatic clear cell RCC before surgical resection. The primary end point was the objective response rate (complete and partial responses) at week 12 and secondary end points included safety, tolerability, clinical and surgical outcomes, and quality of life. Six patients (35%) experienced a partial response and 11 patients (65%) had stable disease. The most common adverse events were diarrhea (n = 12, 70.6%), anorexia, fatigue and hypertension (n = 10, 58.8%), nausea and palmar-plantar erythrodysesthesia syndrome (n = 9, 52.9%). No treatment grade 4 or 5 adverse events related to cabozantinib or surgery occurred. The 1-year disease-free survival and overall survival were 82.4% (95% CI 54.7-93.9%) and 94.1% (95% CI 65-99.1%), respectively. Cabozantinib treatment activated CD8

Indexed as

AnilidesCarcinoma, Renal CellKidney NeoplasmsNeoadjuvant TherapyProtein Kinase InhibitorsPyridinesAdultAgedFemaleHumansMaleMiddle AgedQuality of LifeTreatment OutcomeAnilidescabozantinibProtein Kinase InhibitorsPyridines

Identifiers

PMID40016487

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.